Metformin improves blood glucose levels and BMI in very obese children

December 10, 2012

Metformin therapy has a beneficial treatment effect over placebo in improving body mass index (BMI) and fasting glucose levels in obese children, according to a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM). The study showed reduction in BMI was sustained for six months.

Childhood obesity has increased globally over the last two decades and it is linked to an increase in the diagnosis of type 2 diabetes in childhood, previously a condition that was only diagnosed in adults. is a first line drug for type 2 diabetes, and has been used for many decades. In adults metformin delays the onset of type 2 diabetes, but there is no evidence that the drug has a similar effect on children.

"Our findings provide evidence that a treatment course of metformin is clinically useful, safe and well-tolerated in who are at risk for type 2 diabetes," said Deborah Kendall, MD, of Royal Manchester Children's Hospital in the United Kingdom and lead author of the study. "Metformin may also provide stimulus for lifestyle changes and potentially reduce long-term risk for type 2 diabetes and its associated health problems."

This prospective, randomized, double-blind, -controlled trial was conducted at six pediatric endocrine centers in the United Kingdom and involved 151 obese children and young people with hyperinsulinemia and/or impaired fasting glucose or impaired glucose tolerance. Study participants received either metformin or placebo daily for six months. This trial is the largest of its kind to focus on metformin in obese non-diabetic children and young people.

"Our results show that metformin can improve BMI and blood glucose levels in obese children, but longer term effects such as reduction in the incidence of type 2 diabetes need further study," noted Kendall.

More information: The article, "Metformin in Obese Children and Adolescents: The MOCA Trial," appears in the January 2013 issue of JCEM.

Related Stories

2 drugs better than 1 to treat youth with type 2 diabetes

April 29, 2012

A combination of two diabetes drugs, metformin and rosiglitazone, was more effective in treating youth with recent-onset type 2 diabetes than metformin alone, a study funded by the National Institutes of Health (NIH) has ...

Lung cancer risk unaffected by metformin use in diabetes

August 30, 2012

(HealthDay)—Patients with type 2 diabetes who take metformin do not have a reduced risk of lung cancer, in contrast to previous observational studies, according to a study published online Aug. 24 in Diabetes Care.

Recommended for you

Bacteria may cause type 2 diabetes

June 1, 2015

Bacteria and viruses have an obvious role in causing infectious diseases, but microbes have also been identified as the surprising cause of other illnesses, including cervical cancer (Human papilloma virus) and stomach ulcers ...

'Crosstalk' gives clues to diabetes

June 15, 2015

Sometimes, listening in on a conversation can tell you a lot. For Mark Huising, an assistant professor in the Department of Neurobiology, Physiology and Behavior at the UC Davis College of Biological Sciences, that crosstalk ...

Faster heart rate linked to diabetes risk

May 22, 2015

An association between resting heart rate and diabetes suggests that heart rate measures could identify individuals with a higher future risk of diabetes, according to an international team of researchers.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.